news
« BACK
Pharmacology - Health - 09:06
Health - Pharmacology - 02.10.2023
Health - Pharmacology - 21.09.2023 
Small cell lung cancer: new approach to overcoming chemo-resistance
Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate. SCLC tumours often develop resistance to chemotherapy and thus poor prognosis is due to tumour recurrence which occurs within only five to 14 months after initial diagnosis.
Health - Pharmacology - 18.09.2023
Health - Pharmacology - 06.09.2023
Health - Pharmacology - 01.09.2023 
Gene Mutation in the Immune System: Anti-Diabetes Drugs Make Immune Cells More Effective Again
T cells are an essential component of the immune system - they fight foreign structures such as bacteria and viruses or cancer-related changes in cells. This defense reaction requires energy. Scientists led by the St. Anna Children's Cancer Research Institute, MedUni Vienna and the Marmara University Istanbul have now shown for the first time that a defect in the gene for the transcription factor NFATC1 leads to an immune defect with a disruption of metabolism in T lymphocytes.
Health - Pharmacology - 14.08.2023
Health - Pharmacology - 09.08.2023
Pharmacology - 01.08.2023 
New Study Sheds Light on the gating mechanism of Ion Channels
Breakthrough achieved in elucidating the "gating" process of Kir2 potassium channels Ion channels play a crucial role in many cellular processes, including neuronal communication, muscle contraction or cell proliferation. Most multi subunit ion channels exist in two functional states, either closed or open.
Health - Pharmacology - 31.07.2023 
New method selectively inhibits lactate transporters and creates new therapeutic approaches
A research group led by Giulio Superti-Furga of the Institute of Pharmacology at the Medical University and the CeMM Research Center has developed a new method that makes it possible to specifically inhibit important lactate transporters associated with cancer and numerous other diseases. This could provide a new starting point for the treatment of cancer in particular.
Health - Pharmacology - 28.07.2023 
New method enabling therapeutical targeting of lactate transporters
Scientists from the Giulio Superti-Furga Lab at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, have developed a new method that allows the discovery of specific inhibitors of a lactate transporter associated with cancer and other disease areas. The compound identified in the assay system could provide a new starting point for cancer treatments.
Health - Pharmacology - 05.07.2023 
Peritoneal dialysis: New treatment option against infections
Inflammations of the peritoneum (peritonitis) are as frequent as they are feared complications in peritoneal dialysis, a form of kidney replacement therapy for independent use at home. The bacteria responsible for the life-threatening infections are becoming increasingly resistant to many antibiotics.
Health - Pharmacology - 20.06.2023 
Prediction tool developed to determine benefit of blood cancer treatment
Since its introduction in 2015, a prediction tool developed by the European Society of Medical Oncology (ESMO) has been providing support worldwide in the assessment of the clinical benefits of new cancer therapies. However, previously available versions proved unsuitable for use with malignant diseases of the blood, such as different types of leukaemias or lymphomas.
Health - Pharmacology - 23.05.2023 
Covid-19 vaccination reduces mortality also in critically ill corona patients
A study from the University of Vienna shows a positive effect of vaccination even in patients requiring oxygen. Previous studies have shown that the mortality rate of Corona patients hospitalized and requiring oxygen therapy is similar no matter if they are vaccinated or unvaccinated.
Pharmacology - Health - 17.05.2023
Health - Pharmacology - 10.05.2023
Pharmacology - Health - 04.05.2023
Health - Pharmacology - 04.05.2023
Health - Pharmacology - 27.04.2023
Health - Pharmacology - 05.04.2023
Pharmacology
Results 1 - 20 of 70.
Prediction of the risk of recurrence of venous thrombosis - validity of the Vienna Prediction Model confirmed
A prediction model can be used to identify people affected by venous thromboembolism who have only a low risk of recurrence and may not require long-term blood thinning. The validity of this "Vienna Prediction Model" developed at MedUni Vienna has now been confirmed in a large-scale clinical study and the results have been published in the renowned European Heart Journal.
A prediction model can be used to identify people affected by venous thromboembolism who have only a low risk of recurrence and may not require long-term blood thinning. The validity of this "Vienna Prediction Model" developed at MedUni Vienna has now been confirmed in a large-scale clinical study and the results have been published in the renowned European Heart Journal.
Breakthrough in the fight against resistance in metastatic breast cancer
A team of researchers at the Medical University of Vienna has discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of a specific protein called P-glycoprotein (P-gp). This discovery opens up new possibilities for delaying relapse and is particularly relevant for aggressive triple-negative breast cancer (TNBC), for which there are currently few effective treatments.
A team of researchers at the Medical University of Vienna has discovered that dormant tumor cells surviving chemotherapy can be targeted through the inhibition of a specific protein called P-glycoprotein (P-gp). This discovery opens up new possibilities for delaying relapse and is particularly relevant for aggressive triple-negative breast cancer (TNBC), for which there are currently few effective treatments.
Small cell lung cancer accounts for about 15 percent of all diagnosed lung cancers and is still associated with a high mortality rate. SCLC tumours often develop resistance to chemotherapy and thus poor prognosis is due to tumour recurrence which occurs within only five to 14 months after initial diagnosis.
Autoimmune diseases: Protein discovered as potential new target for therapies
Autoimmune diseases are complex illnesses, the causes of which are diverse and have not yet been fully explained. A research team at MedUni Vienna has now discovered an immunoregulatory protein that could be linked to the development of autoimmune diseases such as rheumatoid arthritis. The identified component of the immune system is called "Rinl", which could provide a new target for the development of immunomodulatory therapies.
Autoimmune diseases are complex illnesses, the causes of which are diverse and have not yet been fully explained. A research team at MedUni Vienna has now discovered an immunoregulatory protein that could be linked to the development of autoimmune diseases such as rheumatoid arthritis. The identified component of the immune system is called "Rinl", which could provide a new target for the development of immunomodulatory therapies.
Cause of rapid loss of vaccination protection in autoimmune diseases identified
People who are treated with TNF-α inhibitors for their autoimmune disease such as Crohn's disease or rheumatoid arthritis lose their vaccination protection significantly earlier than average. The mechanism underlying the early decrease in antibody levels has now been eludicated by a scientific team from MedUni Vienna.
People who are treated with TNF-α inhibitors for their autoimmune disease such as Crohn's disease or rheumatoid arthritis lose their vaccination protection significantly earlier than average. The mechanism underlying the early decrease in antibody levels has now been eludicated by a scientific team from MedUni Vienna.
T cells are an essential component of the immune system - they fight foreign structures such as bacteria and viruses or cancer-related changes in cells. This defense reaction requires energy. Scientists led by the St. Anna Children's Cancer Research Institute, MedUni Vienna and the Marmara University Istanbul have now shown for the first time that a defect in the gene for the transcription factor NFATC1 leads to an immune defect with a disruption of metabolism in T lymphocytes.
Research into use of diabetes medication for treatment of metastatic prostate cancer
Patients with localised prostate cancer have a good chance of survival, but mortality rates among those with advanced, metastatic forms of the condition remain high. Until now, the precise mechanism behind the spread of the tumour has not been fully explained. But an international research team headed by MedUni Vienna has succeeded in decoding the underlying cellular signal pathway and has carried out research using a common diabetes medication that could provide a new treatment option.
Patients with localised prostate cancer have a good chance of survival, but mortality rates among those with advanced, metastatic forms of the condition remain high. Until now, the precise mechanism behind the spread of the tumour has not been fully explained. But an international research team headed by MedUni Vienna has succeeded in decoding the underlying cellular signal pathway and has carried out research using a common diabetes medication that could provide a new treatment option.
Childhood cancer: ’New’ immune system responds better to therapy
Scientists at Medical University Vienna/St. Anna Children's Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children. Crucially, stem cells from a parent provide children with a new immune system that responds much better to immunotherapies.
Scientists at Medical University Vienna/St. Anna Children's Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children. Crucially, stem cells from a parent provide children with a new immune system that responds much better to immunotherapies.
Breakthrough achieved in elucidating the "gating" process of Kir2 potassium channels Ion channels play a crucial role in many cellular processes, including neuronal communication, muscle contraction or cell proliferation. Most multi subunit ion channels exist in two functional states, either closed or open.
A research group led by Giulio Superti-Furga of the Institute of Pharmacology at the Medical University and the CeMM Research Center has developed a new method that makes it possible to specifically inhibit important lactate transporters associated with cancer and numerous other diseases. This could provide a new starting point for the treatment of cancer in particular.
Scientists from the Giulio Superti-Furga Lab at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, have developed a new method that allows the discovery of specific inhibitors of a lactate transporter associated with cancer and other disease areas. The compound identified in the assay system could provide a new starting point for cancer treatments.
Inflammations of the peritoneum (peritonitis) are as frequent as they are feared complications in peritoneal dialysis, a form of kidney replacement therapy for independent use at home. The bacteria responsible for the life-threatening infections are becoming increasingly resistant to many antibiotics.
Since its introduction in 2015, a prediction tool developed by the European Society of Medical Oncology (ESMO) has been providing support worldwide in the assessment of the clinical benefits of new cancer therapies. However, previously available versions proved unsuitable for use with malignant diseases of the blood, such as different types of leukaemias or lymphomas.
A study from the University of Vienna shows a positive effect of vaccination even in patients requiring oxygen. Previous studies have shown that the mortality rate of Corona patients hospitalized and requiring oxygen therapy is similar no matter if they are vaccinated or unvaccinated.
New treatment method for chronic lymphocytic leukemia
A recent study involving MedUni Vienna and University Hospital Vienna has identified a significant advance in the treatment of chronic lymphocytic leukaemia (CLL). The results of the randomised Phase III CLL13 (GAIA) study show that a time-limited and targeted therapy with venetoclax and obinutuzumab is more effective than chemoimmunotherapy in patients without comorbidities.
A recent study involving MedUni Vienna and University Hospital Vienna has identified a significant advance in the treatment of chronic lymphocytic leukaemia (CLL). The results of the randomised Phase III CLL13 (GAIA) study show that a time-limited and targeted therapy with venetoclax and obinutuzumab is more effective than chemoimmunotherapy in patients without comorbidities.
Common Variable Immunodeficiency: Role of B-cell selection identified
Common Variable Immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in humans. Patients suffer from recurrent infections of the upper and lower respiratory tract but many of them also develop more severe symptoms such as granulomas, lymphomas and autoimmune diseases. An international team of researchers led by MedUni Vienna has now discovered why some CVID patients develop an autoimmune disease and others do not.
Common Variable Immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in humans. Patients suffer from recurrent infections of the upper and lower respiratory tract but many of them also develop more severe symptoms such as granulomas, lymphomas and autoimmune diseases. An international team of researchers led by MedUni Vienna has now discovered why some CVID patients develop an autoimmune disease and others do not.
Paradigm shift in the treatment of metastatic colorectal cancer
A global study led by Gerald Prager of the Department of Medicine I and the Comprehensive Cancer Center (CCC) Vienna, a joint MedUni Vienna and University Hospital Vienna facility, and co-workers has demonstrated that the prognosis for patients with metastatic colorectal cancer can be significantly improved.
A global study led by Gerald Prager of the Department of Medicine I and the Comprehensive Cancer Center (CCC) Vienna, a joint MedUni Vienna and University Hospital Vienna facility, and co-workers has demonstrated that the prognosis for patients with metastatic colorectal cancer can be significantly improved.
Faecal incontinence: New surgical treatment being tested at University Hospital Vienna and MedUni Vienna
Faecal incontinence is a major taboo subject and, if left untreated, usually restricts the quality of life of those severely affected. Under the leadership of surgeon Stefan Riss from the Department of General Surgery at MedUni Vienna and the University Hospital Vienna, a study has been launched into a new surgical treatment method.
Faecal incontinence is a major taboo subject and, if left untreated, usually restricts the quality of life of those severely affected. Under the leadership of surgeon Stefan Riss from the Department of General Surgery at MedUni Vienna and the University Hospital Vienna, a study has been launched into a new surgical treatment method.
Chronic thromboembolic pulmonary vascular disease and left heart disease are not mutually exclusive
A long-term analysis designed by Christian Gerges and Irene Lang at the Department of Medicine II of the University Hospital Vienna and MedUni Vienna indicates that one third of patients with chronic thromboembolic pulmonary hypertension (CTEPH) also have left heart disease. In the past, the possibility of overlap between these two conditions had not been considered in the diagnosis and treatment of CTEPH patients.
A long-term analysis designed by Christian Gerges and Irene Lang at the Department of Medicine II of the University Hospital Vienna and MedUni Vienna indicates that one third of patients with chronic thromboembolic pulmonary hypertension (CTEPH) also have left heart disease. In the past, the possibility of overlap between these two conditions had not been considered in the diagnosis and treatment of CTEPH patients.
Morbus Crohn: New imaging technique for effective therapy
Patients suffering from Crohn's disease, a chronic inflammatory intestinal disorder, develop painful constrictions in the bowel. Due to a lack of methods until now, these complications cannot be characterised with sufficient precision to initiate targeted treatment. An interdisciplinary research group at MedUni Vienna has investigated a new imaging technique that can improve the treatment of intestinal strictures.
Patients suffering from Crohn's disease, a chronic inflammatory intestinal disorder, develop painful constrictions in the bowel. Due to a lack of methods until now, these complications cannot be characterised with sufficient precision to initiate targeted treatment. An interdisciplinary research group at MedUni Vienna has investigated a new imaging technique that can improve the treatment of intestinal strictures.
